Ceftazidime-avibactam
Verification of Ceftazidime Avibactam and Ceftolozane Tazobactam Susceptibility Testing Methods against Carbapenem Resistant Enterobacteriaceae and Pseudomonas aeruginosa
... diffusion ceftazidime-avibactam inhibition zones against CRE demonstrated low CA with BMD MICs (76%, compared to 97% CA between Etest and BMD; P ⫽ ...to ceftazidime-avibactam but misclassified ...
7
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
... the ceftazidime/avibactam and meropenem groups, respectively, achieved the primary end point ( - ...both ceftazidime/avibactam and ...a ceftazidime/avibactam MIC ...with ...
16
<p>Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant <em>Klebsiella pneumoniae</em> Isolates in a Chinese Tertiary Hospital</p>
... Ceftazidime-avibactam is a new type of β-lactam/β- lactamase inhibitor combination that is effective against Enterobacteriaceae producing KPCs, OXA-48, carbape- nemases, extended-spectrum β-lactamases, and ...
8
Klebsiella pneumoniae Carbapenemase 2 (KPC 2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime Avibactam: Unique Antibiotic Resistant Phenotypes Emerge from β Lactamase Protein Engineering
... with ceftazidime produced two protein charge envelopes; one was the expected primary charge envelope at approximately 1,100 to 2,000 m/z (29,187 Da mass, corresponding to the predicted mass of 28,719 Da for ...
17
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae
... carbapenemases. Avibactam is a newly developed novel β -lactamase inhibitor in recent years and can efficiently inhibit class A and class D carba- ...inhibitor, avibactam can restore the anti- bacterial ...
9
Efficacy of ceftazidime avibactam in the treatment of infections due to Carbapenem resistant Enterobacteriaceae
... Treatment options for CRE infections are very limited. Polymyxins have been used for the treatment of CRE infec- tions; however, there remain concerns regarding increasing resistance, limited efficacy and toxicity [9 – ...
6
Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype
... Clinical case. A 44-year-old woman with a failed renal transplant who was on peritoneal dialysis presented to a tertiary-care hospital in South Carolina in September 2015 with epigastric pain, nausea, and vomiting for 3 ...
8
Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime Avibactam Resistance in Pseudomonas aeruginosa Acute Infection
... ABSTRACT Strains of Pseudomonas aeruginosa with deficiencies in DNA mismatch repair have been studied in the context of chronic infection, where elevated muta- tional rates (“hypermutation”) may facilitate the acquisition ...
15
Detection and Characterization of β Lactamase Encoding Genes in Carbapenem Non Susceptible Gram Negative Bacteria and Susceptibility of Isolates to Ceftazidime Avibactam at a New York City Community Hospital
... Carbapenem resistant Enterobacteriaceae (CRE), MDR Pseudomonas aeruginosa (MDRPSA) and MDR Acinetobacter (MDRAC) are urgent and serious threats as des- ignated by the Centers for Disease Control and Prevention (CDC) [1]. ...
8
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
... like ceftazidime-avibactam has increased our ability to treat infec- tions caused by multidrug-resistant Gram-negative bacteria, including carba- penemase-producing ...to ceftazidime-avibactam ...
15
<p>Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam</p>
... involved a total of 32 patients, 8 (25%) aging 28 days – 23 months. Patients received a single 2-h intravenous infusion of ceftazidime-avibactam with different dosages based on age and/or body weight. Mean ...
11
<p>Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in <em>bla</em><sub>KPC-3</sub>-harboring <em>Klebsiella pneumoniae</em></p>
... Background: For years, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneu- moniae have represented a serious health problem in hospitals worldwide. Since its approval in 2015, ceftazidime-avibactam ...
6
<p>Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant <em>Klebsiella pneumoniae</em> in a Neonatal Intensive Care Unit in China</p>
... CZA, ceftazidime/avibactam; CZT, ceftolozane/tazobactam; TZP, piperacillin-tazobactam; CSL, cefoperazone/sulbactam; PIP, piperacillin; CZO, cefa- zolin; CMZ, cefmetazole; CXM, cefuroxime; CAZ, ...
8
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
... Ceftazidime/avibactam (CAZ-AVI) is a novel, β- lactam/β-lactamase inhibitor fixed-dose combination drug containing ceftazidime (an established, extended- spectrum and avibactam (a unique, ...
15
<p>First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against <em>Pseudomonas aeruginosa</em> Isolated from Patients with Urinary Tract Infection in Tehran, Iran</p>
... Ceftazidime-avibactam and ceftolozane-tazobactam showed high in vitro activity against a collection of P. aeruginosa isolated from patients with UTI in 2 Iranian hospitals. Thus, these agents could be ...
9
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
... Efficacy Proportion of patients with favourable per-pathogen microbiological response at the EOT, TOC, FU1 and FU2 visits, by ceftazidime- avibactam minimum inhibitory concentration (MIC) categories in the ...
18
Assessment of 30/20 Microgram Disk Content versus MIC Results for Ceftazidime Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa
... testing ceftazidime-avibactam, using the 30/20- g disk and the disk dif- fusion and MIC breakpoints established by the ...displaying ceftazidime-avibactam MIC values close to the ...methods. ...
8
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
... Based on Phase I and Phase II trials, ceftazidime/avibactam is generally well tolerated. All subjects completed the study with no patients requiring discontinuation from the study due to adverse effects ...
8
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
... Figure 4: Per-pathogen response rates at TOC among Gram-negative pathogens isolated at baseline: A clinical response rates per pathogen isolated from urine in cUTI patients; B favourable[r] ...
45
Treatment options for K. pneumoniae P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, colistin and tigecycline. An approach based on the mechanisms of resistance to carbapenems.
... to ceftazidime/avibactam, and against the recently described VEB-25 extended spectrum β-lactamase that has been associated with ceftazidime/avibactam resistance ...to ...
26